EMEA-002901-PIP01-20
Key facts
| Active substance |
Thienopyrimidine Derivative
|
| Therapeutic area |
Pneumology-allergology
|
| Decision number |
P/0459/2021
|
| PIP number |
EMEA-002901-PIP01-20
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of fibrosing Interstitial Lung Diseases (ILD)
|
| Route(s) of administration |
|
| Contact for public enquiries |
Boehringer Ingelheim International GmbH
E-mail: COMMSPaediatrics@boehringer-ingelheim.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|